Published in Drug Week, September 5th, 2003
"To date, more than 300,000 patients have been treated with rituximab worldwide, including patients with indolent and aggressive NHL, Hodgkin's disease, and other B-cell malignancies," wrote J. Boye and colleagues, University Hospital of Cologne, Department of Internal Medicine 1.
"Combination of rituximab with cytotoxic agents or cytokines has been explored in a number of different...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.